Drug Profile
Research programme: phosphodiesterase inhibitors - Acorda Therapeutics
Alternative Names: BTT 5001; ELB 526; ELB-WE-007; WE-1Latest Information Update: 02 Mar 2017
Price :
$50
*
At a glance
- Originator elbion NV
- Developer Biotie Therapies Corp.
- Class 3-ring heterocyclic compounds; Imidazoles; Pyrazines; Pyrimidines; Quinoxalines; Small molecules; Triazines
- Mechanism of Action Phosphodiesterase 10A inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders; Inflammation; Schizophrenia
Most Recent Events
- 04 Nov 2010 Biotie decides to exclusively focus on clinical development and announces a restructuring plan to spin-off its preclinical CNS pipeline and phosphodiesterase enzyme (PDE) inhibitor platform to BioCrea
- 04 Nov 2010 Discontinued - Preclinical for CNS disorders in Germany (PO)
- 04 Nov 2010 Discontinued - Preclinical for Schizophrenia in Europe (unspecified route)